NZ243147A - Pharmaceutical formulation comprising pantoprazole core (a substituted pyridyl methylsulphinyl-1h-benzimidazole) and specific binders with an outer layer which is resistant to gastric juice - Google Patents
Pharmaceutical formulation comprising pantoprazole core (a substituted pyridyl methylsulphinyl-1h-benzimidazole) and specific binders with an outer layer which is resistant to gastric juiceInfo
- Publication number
- NZ243147A NZ243147A NZ243147A NZ24314792A NZ243147A NZ 243147 A NZ243147 A NZ 243147A NZ 243147 A NZ243147 A NZ 243147A NZ 24314792 A NZ24314792 A NZ 24314792A NZ 243147 A NZ243147 A NZ 243147A
- Authority
- NZ
- New Zealand
- Prior art keywords
- core
- resistant
- gastric juice
- physiologically tolerated
- pantoprazole
- Prior art date
Links
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical group COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 210000004051 gastric juice Anatomy 0.000 title claims description 17
- 239000011230 binding agent Substances 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- -1 pyridyl methylsulphinyl-1h-benzimidazole Chemical class 0.000 title description 2
- 229960005019 pantoprazole Drugs 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000008188 pellet Substances 0.000 claims description 21
- 238000000576 coating method Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 150000002484 inorganic compounds Chemical class 0.000 claims 2
- 229910010272 inorganic material Inorganic materials 0.000 claims 2
- 241001125671 Eretmochelys imbricata Species 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- 229960004048 pantoprazole sodium Drugs 0.000 claims 1
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178891 | 1991-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ243147A true NZ243147A (en) | 1995-12-21 |
Family
ID=4218617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ243147A NZ243147A (en) | 1991-06-17 | 1992-06-15 | Pharmaceutical formulation comprising pantoprazole core (a substituted pyridyl methylsulphinyl-1h-benzimidazole) and specific binders with an outer layer which is resistant to gastric juice |
Country Status (34)
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4504000A (en) * | 1993-04-27 | 2000-09-07 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
| SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| DE4324014C2 (de) * | 1993-07-17 | 1995-06-08 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung |
| TW280770B (enExample) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| ATE414509T1 (de) * | 1994-07-08 | 2008-12-15 | Astrazeneca Ab | Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| SK284291B6 (sk) * | 1995-09-21 | 2005-01-03 | Pharma Pass L.L.C. | Farmaceutická kompozícia vo forme tabliet alebo mikrotabliet obsahujúca acidolabilný omeprazol a spôsob jej prípravy |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
| ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
| IN186245B (enExample) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| HUP0100065A2 (hu) * | 1997-12-08 | 2001-08-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| KR100627614B1 (ko) * | 1998-04-20 | 2006-09-25 | 에자이 가부시키가이샤 | 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제 |
| JP4127740B2 (ja) * | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
| EP1736144B1 (en) | 1998-05-18 | 2015-11-11 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
| DE69930648T2 (de) * | 1998-08-12 | 2006-12-21 | Altana Pharma Ag | Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole |
| DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
| SI1187601T1 (sl) | 1999-06-07 | 2005-12-31 | Altana Pharma Ag | Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke |
| SE9902386D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
| ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| CA2387746C (en) * | 1999-10-20 | 2010-06-29 | Koji Ukai | Methods for stabilizing benzimidazole-based compounds |
| DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
| DK1108425T3 (da) * | 1999-12-16 | 2005-09-26 | Medinfar Produtos Farmaceutico | Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler |
| AU2277101A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| SK287105B6 (sk) * | 1999-12-20 | 2009-12-07 | Schering Corporation | Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| KR20030059318A (ko) * | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제 |
| CN100408029C (zh) | 2001-09-28 | 2008-08-06 | 麦克内尔-Ppc股份有限公司 | 有镶嵌部分的组合剂型 |
| US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
| US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US8449911B2 (en) * | 2003-03-12 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
| AU2003245033A1 (en) * | 2003-05-08 | 2004-11-26 | Podili Khadgapathi | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation |
| PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| US20050147663A1 (en) * | 2003-07-17 | 2005-07-07 | Mohan Mailatur S. | Method of treatment for improved bioavailability |
| NZ544608A (en) * | 2003-07-17 | 2008-07-31 | Reddys Lab Ltd Dr | Pharmaceutical compositions having a swellable coating comprising prolamin |
| US20050042277A1 (en) * | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004271747A1 (en) * | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Use of known active ingredients as radical scavengers |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| WO2005034924A1 (en) * | 2003-10-14 | 2005-04-21 | Natco Pharma Limited | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation |
| US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
| AU2004287373A1 (en) * | 2003-10-31 | 2005-05-19 | Dexcel Ltd. | Stable lansoprazole formulation |
| WO2005046634A2 (de) * | 2003-11-14 | 2005-05-26 | Siegfried Generics International Ag | Magensaftresistente verabreichungsform |
| HU227317B1 (en) * | 2003-11-25 | 2011-03-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Enteric coated tablet containing pantoprazole |
| EP1694300A4 (en) * | 2003-12-09 | 2009-04-29 | Pharmasset Inc | DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY |
| JP2007522217A (ja) * | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
| PL2156824T3 (pl) * | 2004-03-25 | 2013-03-29 | Astellas Pharma Inc | Kompozycja solifenacyny lub jej soli do zastosowania w formulacji stałej |
| WO2005092336A1 (ja) * | 2004-03-26 | 2005-10-06 | Eisai R&D Management Co., Ltd. | 溶出制御製剤とその製造方法 |
| ES2376466T3 (es) | 2004-05-07 | 2012-03-14 | Nycomed Gmbh | Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación. |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
| US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| EP1830822A1 (en) * | 2004-12-24 | 2007-09-12 | LEK Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
| CN101141961B (zh) * | 2004-12-27 | 2011-07-06 | 安斯泰来制药株式会社 | 索非那新或其盐的稳定的颗粒状药物组合物 |
| EP1833469A2 (en) * | 2005-01-03 | 2007-09-19 | Lupin Ltd. | Pharmaceutical composition of acid labile substances |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| CA2608444A1 (en) * | 2005-05-13 | 2007-03-15 | Combino Pharm, S.L. | Formulations containing pantoprazole free acid and its salts |
| US7815939B2 (en) * | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
| EP1747776A1 (en) * | 2005-07-29 | 2007-01-31 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising granular pantoprazole |
| JPWO2007037259A1 (ja) * | 2005-09-29 | 2009-04-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 生体内での崩壊性を向上させたパルス製剤 |
| WO2007041630A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| WO2007074856A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤の製造法 |
| EP1973532A1 (en) * | 2006-01-16 | 2008-10-01 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
| EP2026768B1 (en) * | 2006-06-01 | 2018-02-28 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| GB2459393B (en) | 2006-10-05 | 2010-09-08 | Santarus Inc | Novel capsule formulation for the proton pump inhibitor omeprazole |
| WO2008062320A2 (en) * | 2006-10-06 | 2008-05-29 | Eisai R&D Management Co., Ltd | Extended release formulations of a proton pump inhibitor |
| EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| RU2491075C2 (ru) | 2006-12-22 | 2013-08-27 | Айронвуд Фармасьютикалз, Инк. | Способы и композиции для лечения расстройств пищевода |
| ES2560899T3 (es) | 2007-09-14 | 2016-02-23 | Wockhardt Limited | Composiciones de diacereína |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| DE102010052847A1 (de) * | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
| EP3991719A1 (en) | 2013-01-15 | 2022-05-04 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| WO2016126625A1 (en) | 2015-02-03 | 2016-08-11 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN108065443B (zh) * | 2017-12-30 | 2020-02-28 | 厦门金达威维生素有限公司 | 斥水型双包被微胶囊及其制备方法 |
| CN114569579B (zh) | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
| EP4598528A1 (en) | 2022-10-04 | 2025-08-13 | Arsenil Zabirnyk | Inhibition of aortic valve calcification |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
-
1992
- 1992-06-02 YU YU57692A patent/YU48263B/sh unknown
- 1992-06-03 IL IL10209692A patent/IL102096A/en not_active IP Right Cessation
- 1992-06-12 HR HR01788/91-0A patent/HRP920162B1/xx not_active IP Right Cessation
- 1992-06-13 PL PL92301957A patent/PL169951B1/pl unknown
- 1992-06-13 CZ CS932764A patent/CZ281697B6/cs not_active IP Right Cessation
- 1992-06-13 EP EP92912364A patent/EP0589981B1/de not_active Expired - Lifetime
- 1992-06-13 KR KR1019930703898A patent/KR100254021B1/ko not_active Expired - Lifetime
- 1992-06-13 JP JP51105392A patent/JP3338052B2/ja not_active Expired - Lifetime
- 1992-06-13 DE DE4219390A patent/DE4219390A1/de not_active Ceased
- 1992-06-13 HK HK98105037A patent/HK1005851A1/xx not_active IP Right Cessation
- 1992-06-13 CA CA002109697A patent/CA2109697C/en not_active Expired - Lifetime
- 1992-06-13 ES ES92912364T patent/ES2096080T3/es not_active Expired - Lifetime
- 1992-06-13 DK DK92912364.4T patent/DK0589981T3/da active
- 1992-06-13 EP EP92110021A patent/EP0519365A1/de active Pending
- 1992-06-13 SK SK1287-93A patent/SK278566B6/sk not_active IP Right Cessation
- 1992-06-13 WO PCT/EP1992/001341 patent/WO1992022284A1/de not_active Ceased
- 1992-06-13 RU RU9293058536A patent/RU2089180C1/ru active
- 1992-06-13 AU AU19746/92A patent/AU683411B2/en not_active Expired
- 1992-06-13 CA CA002524168A patent/CA2524168A1/en not_active Expired - Lifetime
- 1992-06-13 DE DE59207438T patent/DE59207438D1/de not_active Expired - Lifetime
- 1992-06-13 UA UA93004305A patent/UA32525C2/uk unknown
- 1992-06-13 US US08/167,961 patent/US5997903A/en not_active Expired - Lifetime
- 1992-06-13 RO RO93-01691A patent/RO117502B1/ro unknown
- 1992-06-13 AT AT92912364T patent/ATE144416T1/de active
- 1992-06-15 ZW ZW93/92A patent/ZW9392A1/xx unknown
- 1992-06-15 NZ NZ243147A patent/NZ243147A/en not_active IP Right Cessation
- 1992-06-16 ZA ZA924386A patent/ZA924386B/xx unknown
- 1992-06-17 CN CN92104690A patent/CN1037932C/zh not_active Expired - Lifetime
- 1992-06-17 SI SI19929200111A patent/SI9200111A/sl unknown
- 1992-06-17 MX MX9202961A patent/MX9202961A/es unknown
- 1992-07-01 IE IE921733A patent/IE77640B1/en not_active IP Right Cessation
- 1992-07-07 TW TW081105370A patent/TW224429B/zh not_active IP Right Cessation
-
1993
- 1993-12-10 BG BG98286A patent/BG61796B1/bg unknown
- 1993-12-16 FI FI935677A patent/FI101598B/fi not_active IP Right Cessation
- 1993-12-16 NO NO934648A patent/NO303714B1/no not_active IP Right Cessation
-
1996
- 1996-12-24 GR GR960403621T patent/GR3022154T3/el unknown
-
1997
- 1997-10-23 LV LVP-97-207A patent/LV11982B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5997903A (en) | Oral-administration forms of a medicament containing pantoprazol | |
| EP1213015B1 (en) | Oral pharmaceutical composition with delayed release of proton pump inhibitors | |
| EP0960620B1 (en) | A stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole | |
| EP1108425B1 (en) | New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles | |
| HK1005851B (en) | Oral-administration forms of a medicament containing pantoprazol | |
| WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
| IL171365A (en) | Dosage forms for oral administration of magnesium salt of pantoprazole | |
| US8865212B2 (en) | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same | |
| WO2005034924A1 (en) | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation | |
| WO2004098573A1 (en) | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation | |
| HU227317B1 (en) | Enteric coated tablet containing pantoprazole | |
| CN100488507C (zh) | 含有泮托拉唑作为活性成分的剂型 | |
| WO2006085723A1 (en) | The enteric coated pharmaceutical oral formulations comprising acid-labile active substances, and a method thereof | |
| HU219247B (en) | Oral administration form of a medicament containing pantoprazol | |
| KR20070020977A (ko) | 판토프라졸 함유 경구용 약제 제형 | |
| HK1023944A (en) | A stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole | |
| HK1039742B (en) | New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: NYCOMED GMBH, DE Free format text: OLD OWNER(S): ALTANA PHARMA AG |
|
| EXPY | Patent expired |